Progress towards development of an HIV vaccine: report of the AIDS Vaccine 2009 Conference

被引：36

作者：

Ross, Anna Laura ^{[8
]}

Brave, Andreas ^{[6
,7
]}

Scarlatti, Gabriella ^{[5
]}

Manrique, Amapola ^{[4
]}

Buonaguro, Luigi ^{[1
,2
,3
]}

机构：

[1] Fdn G Pascale, Ist Nazl Tumori, Mol Biol Lab, I-80131 Naples, Italy

[2] Fdn G Pascale, Natl Canc Inst, Viral Oncogenesis & AIDS Reference Ctr, I-80131 Naples, Italy

[3] Univ Maryland, Sch Med, Inst Human Virol, Baltimore, MD 21201 USA

[4] Global HIV Vaccine Enterprise, New York, NY USA

[5] Ist Sci San Raffaele, Div Immunol Transplant & Infect Dis, Viral Evolut & Transmiss Unit, I-20132 Milan, Italy

[6] Swedish Inst Infect Dis Control, Dept Virol, Stockholm, Sweden

[7] Swedish Inst Infect Dis Control, Karolinska Inst, Dept Microbiol Tumour & Cell Biol, Stockholm, Sweden

[8] French Natl Agcy Res AIDS & Viral Hepatitis, HIV Vaccine Res Unit, Paris, France

来源：

LANCET INFECTIOUS DISEASES | 2010年 / 10卷 / 05期

关键词：

HUMAN-IMMUNODEFICIENCY-VIRUS; T-CELL RESPONSES; HUMAN MONOCLONAL-ANTIBODY; ELICITS NEUTRALIZING ANTIBODIES; RECOMBINANT MEASLES VIRUSES; VESICULAR STOMATITIS-VIRUS; HIV-1/SIV CHIMERIC VIRUS; MUCOSAL HOMING PHENOTYPE; YELLOW-FEVER VACCINE; IMMUNE-RESPONSES;

D O I：

10.1016/S1473-3099(10)70069-4

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

The search for an HIV/AIDS vaccine is steadily moving ahead, generating and validating new concepts in terms of novel vectors for antigen delivery and presentation, new vaccine and adjuvant strategies, alternative approaches to design HIV-1 antigens for eliciting protective cross-neutralising antibodies, and identification of key mechanisms in HIV infection and modulation of the immune system. All these different perspectives are contributing to the unprecedented challenge of developing a protective HIV-1 vaccine. The high scientific value of this massive effort is its great impact on vaccinology as a whole, providing invaluable scientific information for the current and future development of new preventive vaccine as well as therapeutic knowledge-based infectious-disease and cancer vaccines.

引用

页码：305 / 316

页数：12

共 152 条

[1] Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D [J].

Abbink, Peter ;

Lemckert, Angelique A. C. ;

Ewald, Bonnie A. ;

Lynch, Diana M. ;

Denholtz, Matthew ;

Smits, Shirley ;

Holterman, Lennart ;

Damen, Irma ;

Vogels, Ronald ;

Thorner, Anna R. ;

O'Brien, Kara L. ;

Carville, Angela ;

Mansfield, Keith G. ;

Goudsmit, Jaap ;

Havenga, Menzo J. E. ;

Barouch, Dan H. .

JOURNAL OF VIROLOGY, 2007, 81 (09) :4654-4663

[2]

Alter Galit, 2009, Hum Vaccin, V5, P119

[3] Influence of HLA-B57 on clinical presentation and viral control during acute HIV-1 infection [J].

Altfeld, M ;

Addo, MA ;

Rosenberg, ES ;

Hecht, FA ;

Lee, PK ;

Vogel, M ;

Yu, XG ;

Draenert, R ;

Johnston, MN ;

Strick, D ;

Allen, TA ;

Feeney, ME ;

Kahn, JO ;

Sekaly, RP ;

Levy, JA ;

Rockstroh, JK ;

Goulder, PJR ;

Walker, BD .

AIDS, 2003, 17 (18) :2581-2591

[4] Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine [J].

Amara, RR ;

Villinger, F ;

Altman, JD ;

Lydy, SL ;

O'Neil, SP ;

Staprans, SI ;

Montefiori, DC ;

Xu, Y ;

Herndon, JG ;

Wyatt, LS ;

Candido, MA ;

Kozyr, NL ;

Earl, PL ;

Smith, JM ;

Ma, HL ;

Grimm, BD ;

Hulsey, ML ;

Miller, J ;

McClure, HM ;

McNicholl, JM ;

Moss, B ;

Robinson, HL .

SCIENCE, 2001, 292 (5514) :69-74

[5] Immature monocyte derived dendritic cells gene expression profile in response to Virus-Like Particles stimulation -: art. no. 45 [J].

Aricò, E ;

Wang, E ;

Tornesello, ML ;

Tagliamonte, M ;

Lewis, GK ;

Marincola, FM ;

Buonaguro, FM ;

Buonaguro, L .

JOURNAL OF TRANSLATIONAL MEDICINE, 2005, 3 (1)

[6] Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection [J].

Baba, TW ;

Liska, V ;

Hofmann-Lehmann, R ;

Vlasak, J ;

Xu, WD ;

Ayehunie, S ;

Cavacini, LA ;

Posner, MR ;

Katinger, H ;

Stiegler, G ;

Bernacky, BJ ;

Rizvi, TA ;

Schmidt, R ;

Hill, LR ;

Keeling, ME ;

Lu, YC ;

Wright, JE ;

Chou, TC ;

Ruprecht, RM .

NATURE MEDICINE, 2000, 6 (02) :200-206

[7] First-in-human Phase 1 safety and immunigenicity of an adenovirus serotype 26 HIV-1 vaccine vector [J].

Baden, L. R. ;

Dolin, R. ;

O'Brien, K. L. ;

Abbink, P. ;

La Porte, A. ;

Seaman, M. S. ;

Choi, E. ;

Tucker, R. ;

Weitjens, M. ;

Pau, M. G. ;

Goudsmit, J. ;

Barouch, D. H. .

RETROVIROLOGY, 2009, 6

[8]

BAROUCH D, 2009, P AIDS VACC 2009 C P

[9] Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity [J].

Barouch, DH ;

Pau, MG ;

Custers, JHHV ;

Koudstaal, W ;

Kostense, S ;

Havenga, MJE ;

Truitt, DM ;

Sumida, SM ;

Kishko, MG ;

Arthur, JC ;

Korioth-Schmitz, B ;

Newberg, MH ;

Gorgone, DA ;

Lifton, MA ;

Panicali, DL ;

Nabel, GJ ;

Letvin, NL ;

Goudsmit, J .

JOURNAL OF IMMUNOLOGY, 2004, 172 (10) :6290-6297

[10]

BARRESINOUSSI F, 2009, P AIDS VACC 2009 C P

← 1 2 3 4 5 6 7 8 9 10 →